Migrén: vizsgálatok itt: Lengyelország
11 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleRandomized Study in Children and Adolescents With Migraine: Acute Treatment
- Where
- Cracow, Poznan, Wrocław
- Életkor
- 6 év to 17 év
- People
- 2100 worldwide
- Run by
- Pfizer
See details and how to joinNCT04649242 · EU 2024-512743-23-00 - 3. fázisTaking peopleLong-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
- Where
- Cracow, Poznan, Wroclaw
- Életkor
- 6 év to 17 év
- People
- 600 worldwide
- Run by
- Pfizer
See details and how to joinNCT04743141 · EU 2024-512744-32-00 - 3. fázisTaking peopleA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- Where
- Bydgoszcz, Cracow, Lublin, Oswiecim, Warsaw, Wrocław
- Életkor
- 12 év to 17 év
- People
- 285 worldwide
- Run by
- H. Lundbeck A/S
See details and how to joinNCT04965675 · EU 2024-510656-13-00 - 3. fázisTaking peopleEfficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- Where
- Cracow, Katowice, Lublin, Poznan, Warsaw, Wroclaw, Wrocław
- Életkor
- 6 év to 17 év
- People
- 640 worldwide
- Run by
- Pfizer
See details and how to joinNCT05156398 · EU 2024-512382-13-00 - 3. fázisTaking peopleA Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
- Where
- Bydgoszcz, Cracow, Lublin, Oswiecim, Warsaw, Wrocław
- Életkor
- 6 év to 17 év
- People
- 600 worldwide
- Run by
- H. Lundbeck A/S
See details and how to joinNCT05164172 · EU 2022-502917-27-00 - 3. fázisTaking peopleA Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- Where
- Krakow, Lublin, Oświęcim, Warsaw
- Életkor
- 6 év to 17 év
- People
- 315 worldwide
- Run by
- H. Lundbeck A/S
See details and how to joinNCT05897320 · EU 2022-502538-14-00 - 3. fázisTaking peopleA Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
- Where
- Bydgoszcz, Cracow, Poznan, Warsaw, Wrocław
- Életkor
- 12 év to 17 év
- People
- 420 worldwide
- Run by
- AbbVie
See details and how to joinNCT06810505 · EU 2024-513836-28-00 - 3. fázisTaking peopleA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
- Where
- Bydgoszcz, Cracow, Lublin, Poznan, Warsaw, Wroclaw
- Életkor
- 6 év to 17 év
- People
- 450 worldwide
- Run by
- AbbVie
See details and how to joinNCT05711394 · EU 2022-501100-94-00 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- Where
- Cracow, Katowice, Lublin, Oswiecim, Warsaw, Wroclaw
- Életkor
- 18 év to 45 év
- People
- 723 worldwide
- Run by
- Pfizer
See details and how to joinNCT06641466 · EU 2024-517121-10-00 - No phaseTaking peopleReal-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
- Where
- Wroclaw
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Hospital Universitari Vall d'Hebron Research Institute
See details and how to joinNCT07159750 - 3. fázisCsak meghívásosLong-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
- Where
- Bydgoszcz, Cracow, Lublin, Poznan, Warsaw, Wroclaw
- Életkor
- 6 év to 17 év
- People
- 650 worldwide
- Run by
- AbbVie
See details and how to joinNCT05707949 · EU 2022-501099-24-00